Prompt versus preemptive intervention for EBV lymphoproliferative disease

Blood

Volumn 103, Issue 10, 2004, Pages 3979-3981

  Wagner, Hans Joachim ^b   Cheng, Yee Chung ^b   Huls, M Helen ^b   Gee, Adrian P ^b   Kuehnle, Ingrid ^b   Krance, Robert A ^b   Brenner, Malcolm K ^b   Rooney, Cliona M ^b   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; RITUXIMAB; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; HURLER SYNDROME; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE TRANSFER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WISKOTT ALDRICH SYNDROME;

EID: 2342541670     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4287     Document Type: Article

References (17)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
2. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
3. van Esser JW, Niesters HG, van der HB, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenetic stem cell transplantation. Blood. 2002;99: 4364-4369.
4. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99: 2712-2719.
5. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
6. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
7. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95: 807-814.
8. Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol. 1996;89:98-103.
9. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-Induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654-3661.
10. van Esser JW, van der HB, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T cell-depleted SCT. Blood. 2001;98:972-978.
11. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543-558.
12. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet. 1997;350:767-770.
13. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208-215.
14. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein Barr virus (EBV)-specific cytotoxic T cells (CTL) for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72:1078-1086.
15. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9-13.
16. Savoldo B, Huis MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059-4066.
17. Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002;84:175-201.